Molecular characterization of hepatitis B virus strains circulating in Belgian patients co-infected with HIV and HBV: Overt and occult infection

Journal of Medical Virology

Volumn 83, Issue 11, 2011, Pages 1876-1884

  Pourkarim, Mahmoud Reza ^a,b   Lemey, Philippe ^a   Amini Bavil Olyaee, Samad ^c   Houspie, Lieselot ^a   Verbeeck, Jannick ^a   Rahman, Mustafizur ^d   Maes, Piet ^a   Vanwijngaerden, Eric ^e   Nevens, Frederik ^e   van Ranst, Marc ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

^d INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Belgium; Co infection; Full length genome; Hepatitis B virus; HIV; Occult

Indexed keywords

HEPATITIS B CORE ANTIBODY;

ADULT; ARTICLE; BELGIUM; CLINICAL ARTICLE; DISEASE COURSE; END STAGE LIVER DISEASE; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIXED INFECTION; NUCLEOTIDE SEQUENCE; UNINDEXED SEQUENCE; VIRUS DETECTION; VIRUS GENOME; VIRUS STRAIN; VIRUS TRANSMISSION;

ADULT; BELGIUM; CLUSTER ANALYSIS; DNA, VIRAL; EVOLUTION, MOLECULAR; FEMALE; GENOME, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHYLOGENY; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

HEPATITIS B VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 80052700662     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.22174     Document Type: Article

References (54)

1. Alvarado-Esquivel C, Sablon E, Conde-Gonzalez CJ, Juarez-Figueroa L, Ruiz-Maya L, Aguilar-Benavides S. 2006. Molecular analysis of hepatitis B virus isolates in Mexico: Predominant circulation of hepatitis B virus genotype H. World J Gastroenterol 12: 6540-6545.
2. Amini-Bavil-Olyaee S, Sarrami-Forooshani R, Adeli A, Sabahi F, Abachi M, Azizi M, Mahboudi F. 2005. Complete genomic sequence and phylogenetic relatedness of hepatitis B virus isolates from Iran. J Med Virol 76: 318-326.
3. Amini-Bavil-Olyaee S, Trautwein C, Tacke F. 2007. Relevance of hepatitis B virus genome variability in organ transplantation. Hepat Mon 7: 7.
4. Bartholomeusz A, Schaefer S. 2004. Hepatitis B virus genotypes: Comparison of genotyping methods. Rev Med Virol 14: 3-16.
5. Bottecchia M, Souto FJ, O KM, Amendola M, Brandao CE, Niel C, Gomes SA. 2008. Hepatitis B virus genotypes and resistance mutations in patients under long term lamivudine therapy: Characterization of genotype G in Brazil. BMC Microbiol 8: 11.
6. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, Glebe D. 2009. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 49: 1621-1629.
7. Carman WF. 1997. The clinical significance of surface antigen variants of hepatitis B virus. J Viral Hepat 4: 11-20.
8. Datta S, Banerjee A, Chandra PK, Chowdhury A, Chakravarty R. 2006. Genotype, phylogenetic analysis, and transmission pattern of occult hepatitis B virus (HBV) infection in families of asymptomatic HBsAg carriers. J Med Virol 78: 53-59.
9. De Maddalena C, Giambelli C, Tanzi E, Colzani D, Schiavini M, Milazzo L, Bernini F, Ebranati E, Cargnel A, Bruno R, Galli M, Zehender G. 2007. High level of genetic heterogeneity in S and P genes of genotype D hepatitis B virus. Virology 365: 113-124.
10. Echevarria JM, Avellon A. 2006. Hepatitis B virus genetic diversity. J Med Virol 78: S36-S42.
11. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 1329-1339.
12. Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. 2002. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood 100: 2637-2641.
13. Holinger F, Habibollahi p, Daneshmand A, Alavian SM. 2010. Occult hepatitis B infection in chronic hemodialysis patients: Current concepts and strategy. Hepat Mon 10: 6.
14. Hu KQ. 2002. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 9: 243-257.
15. Jardi R, Rodriguez-Frias F, Schaper M, Giggi E, Tabernero D, Homs M, Esteban R, Buti M. 2008. Analysis of hepatitis B genotype changes in chronic hepatitis B infection: Influence of antiviral therapy. J Hepatol 49: 695-701.
16. Kimbi GC, Kramvis A, Kew MC. 2004. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J Gen Virol 85: 1211-1220.
17. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, Zilmer K, Vella S, Kirk O, Lundgren JD. 2005. Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 19: 593-601.
18. Koppelman MH, Zaaijer HL. 2004. Diversity and origin of hepatitis B virus in Dutch blood donors. J Med Virol 73: 29-32.
19. Lacombe K, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, Mialhes P, Molina JM, Lascoux-Combe C, Wendum D, Carrat F, Zoulim F. 2006. Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIV. AIDS 20: 419-427.
20. Laufer N, Cassino L, Bolcic F, Moretti F, Reynoso R, Bouzas MB, Cahn P, Salomon H, Quarleri J. 2008. Uncommon hepatitis B virus and/or hepatitis C virus occult infection in HIV-positive patients with abnormal level of hepatic enzyme. J Acquir Immune Defic Syndr 49: 233-234.
21. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, Ruxrungtham K, Lange JM, Phanuphak P, Cooper DA. 2003. Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17: 2191-2199.
22. Martin CM, Welge JA, Shire NJ, Rouster SD, Shata MT, Sherman KE, Blackard JT. 2010. Genomic variability associated with the presence of occult hepatitis B virus in HIV co-infected individuals. J Viral Hepat 17: 588-597.
23. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, Chiba T. 2000. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology (Baltimore. MD) 31: 488-495.
24. Micalessi MI, De Cock L, Vranckx R. 2005. Hepatitis B virus (HBV) genotyping in Belgian patients with chronic HBV infection. Clin Microbiol Infect 11: 499-501.
25. Mwangi J, Nganga Z, Songok E, Kinyua J, Lagat N, Muriuki J, Lihana R, Khamadi S, Osman S, Lwembe R, Kiptoo M, Mwau M, Chirchir R, Mpoke S, Nyamongo J, Okoth F, Yamada R, Kageyama S, Ichimura H. 2008. Molecular genetic diversity of hepatitis B virus in Kenya. Intervirology 51: 417-421.
26. Osiowy C. 2006. Detection of HBsAg mutants. J Med Virol 78: S48-S51.
27. Osiowy C, Gordon D, Borlang J, Giles E, Villeneuve JP. 2008. Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada. J Gen Virol 89: 3009-3015.
28. Perez-Olmeda M, Nunez M, Garcia-Samaniego J, Rios P, Gonzalez-Lahoz J, Soriano V. 2003. Distribution of hepatitis B virus genotypes in HIV-infected patients with chronic hepatitis B: Therapeutic implications. AIDS Res Hum Retroviruses 19: 657-659.
29. Pollicino T, Raffa G, Costantino L, Lisa A, Campello C, Squadrito G, Levrero M, Raimondo G. 2007. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology (Baltimore, MD) 45: 277-285.
30. Pourkarim MR, Verbeeck J, Rahman M, Amini-Bavil-Olyaee S, Forier AM, Lemey P, Maes P, Van Ranst M. 2009. Phylogenetic analysis of hepatitis B virus full-length genomes reveals evidence for a large nosocomial outbreak in Belgium. J Clin Virol 46: 61-68.
31. Pourkarim MR, Amini-Bavil-Olyaee S, Verbeeck J, Lemey P, Zeller M, Rahman M, Maes P, Nevens F, Van Ranst M. 2010a. Molecular evolutionary analysis and mutational pattern of full-length genomes of hepatitis B virus isolated from Belgian patients with different clinical manifestations. J Med Virol 82: 379-389.
32. Pourkarim MR, Lemey P, Amini-Bavil-Olyaee S, Maes P, Van Ranst M. 2010b. Novel hepatitis B virus subgenotype A6 in African-Belgian patients. J Clin Virol 47: 93-96.
33. Quarleri J, Moretti F, Bouzas MB, Laufer N, Carrillo MG, Giuliano SF, Perez H, Cahn P, Salomon H. 2007. Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B. AIDS Res Hum Retroviruses 23: 525-531.
34. Ramezani A, Banifazl M, Mohraz M, Rasoolinejad M, Aghakhani A. 2011. Occult hepatitis B virus infection: A major concern in HIV-infected patients. Hepat Mon 11: 4.
35. Ramos B, Nunez M, Martin-Carbonero L, Sheldon J, Rios P, Labarga P, Romero M, Barreiro P, Garcia-Samaniego J, Soriano V. 2007. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 44: 557-561.
36. Rantala M, van de Laar MJ. 2008. Surveillance and epidemiology of hepatitis B and C in Europe-A review. Euro Surveill 13: 1-8.
37. Sanchez LV, Tanaka Y, Maldonado M, Mizokami M, Panduro A. 2007. Difference of hepatitis B virus genotype distribution in two groups of Mexican patients with different risk factors. High prevalence of genotype H and G. Intervirology 50: 9-15.
38. Schaefer S. 2007. Hepatitis B virus genotypes in Europe. Hepatol Res 37: S20-S26.
39. Seddigh-Tonekaboni S, Lim WL, Young B, Hou JL, Waters J, Luo KX, Thomas HC, Karayiannis P. 2001. Hepatitis B surface antigen variants in vaccines, blood donors and an interferon-treated patient. J Viral Hepat 8: 154-158.
40. Sheldon J, Ramos B, Garcia-Samaniego J, Rios P, Bartholomeusz A, Romero M, Locarnini S, Zoulim F, Soriano V. 2007. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 46: 279-282.
41. Shibayama T, Masuda G, Ajisawa A, Hiruma K, Tsuda F, Nishizawa T, Takahashi M, Okamoto H. 2005. Characterization of seven genotypes (A to E, G and H) of hepatitis B virus recovered from Japanese patients infected with human immunodeficiency virus type. J Med Virol 76: 24-32.
42. Shire NJ, Rouster SD, Rajicic N, Sherman KE. 2004. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36: 869-875.
43. Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, Sherman KE. 2007. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 44: 309-314.
44. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J. 2008. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 22: 1399-1410.
45. Sulkowski MS. 2008. Viral hepatitis and HIV coinfection. J Hepatol 48: 353-367.
46. Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F. 2006. Genome-wide characterisation of hepatitis B mutations involved in clinical outcome. Heredity 97: 389-397.
47. Thio CL, Seaberg EC, Skolasky R, Jr., Phair J, Visscher B, Munoz A, Thomas DL. 2002. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
48. Tian Y, Xu Y, Zhang Z, Meng Z, Qin L, Lu M, Yang D. 2007. The amino acid residues at positions 120 to 123 are crucial for the antigenicity of hepatitis B surface antigen. J Clin Microbiol 45: 2971-2978.
49. Trimoulet P, Boutonnet M, Winnock M, Faure M, Loko MA, De Ledinghen V, Bernard PH, Castera L, Foucher J, Dupon M, Ragnaud JM, Lafon ME, Couzigou P, Dabis F, Fleury H, Neau D. 2007. Hepatitis B virus genotypes: A retrospective survey in Southwestern France, 1999-2004. Gastroenterol Clin Biol 31: 1088-1094.
50. Trinks J, Cuestas ML, Tanaka Y, Mathet VL, Minassian ML, Rivero CW, Benetucci JA, Gimenez ED, Segura M, Bobillo MC, Corach D, Ghiringhelli PD, Sanchez DO, Avila MM, Peralta LA, Kurbanov F, Weissenbacher MC, Simmonds P, Mizokami M, Oubina JR. 2008. Two simultaneous hepatitis B virus epidemics among injecting drug users and men who have sex with men in Buenos Aires, Argentina: characterization of the first D/A recombinant from the American continent. J Viral Hepat 15: 827-838.
51. Weber B. 2006. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 78: S59-S65.
52. Yuki N, Nagaoka T, Yamashiro M, Mochizuki K, Kaneko A, Yamamoto K, Omura M, Hikiji K, Kato M. 2003. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology (Baltimore, MD) 37: 1172-1179.
53. Zaaijer HL, Torres P, Ontanon A, Ponte LG, Koppelman MH, Lelie PN, Hemert FJ, Boot HJ. 2008. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. J Med Virol 80: 1344-1349.
54. Zahn A, Li C, Danso K, Candotti D, Owusu-Ofori S, Temple J, Allain JP. 2008. Molecular characterization of occult hepatitis B virus in genotype E-infected subjects. J Gen Virol 89: 409-418.